Core Viewpoint - Republic Power Group Limited announced a 1-for-20 reverse share split for its Class A and Class B ordinary shares, effective February 23, 2026, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1]. Group 1: Reverse Share Split Details - The reverse share split will adjust the Class A Ordinary Shares' par value from $0.000625 to $0.0125 per share, with trading on Nasdaq continuing under the symbol "RPGL" [1]. - The number of issued and outstanding Class A Ordinary Shares will decrease from 62,025,000 to approximately 3.1 million shares, subject to adjustments for fractional shares [1]. - No fractional shares will be issued; all fractional interests will be rounded up to the nearest whole number of Class A Ordinary Shares [1]. Group 2: Company Background - Republic Power Group Limited is based in Singapore and specializes in developing customized enterprise resource planning (ERP) software solutions, consulting, technical support services, and peripheral hardware [1].

Core Insights - Clearmind Medicine is advancing its proprietary compound MEAI, a non-hallucinogenic neuroplastogen, as a potential next-generation treatment for obesity, targeting the psychological roots of eating behaviors [1] - The obesity treatment market is projected to exceed $100 billion, indicating significant growth potential for innovative therapies like MEAI [1] Company Overview - Clearmind Medicine is a clinical-stage biotech company focused on developing novel therapeutics to address under-treated health issues, particularly obesity [1] - MEAI is designed to disrupt rigid behavioral patterns, promote cognitive flexibility, and enhance neuronal plasticity while providing metabolic benefits [1] Mechanism of Action - Unlike GLP-1-based treatments that primarily target gut hormones, MEAI works directly in the brain by modulating the monoaminergic system, addressing compulsive eating behaviors and food addiction [1] - Pre-clinical studies indicate that MEAI can modulate energy balance, boost fat burning, improve insulin sensitivity, and significantly decrease fat mass while preserving lean muscle mass [1] Comparative Analysis - MEAI shows a potential weight loss profile of approximately 20% reduction in pre-clinical studies, prioritizing fat loss and muscle preservation, compared to GLP-1 drugs which show a 15-22% reduction often accompanied by muscle loss [1] - MEAI has a favorable safety profile with no reported sedation or hyperactivity, contrasting with common gastrointestinal issues associated with GLP-1 drugs [1] Strategic Developments - Clearmind has filed new patent applications targeting obesity and metabolic disorders and is collaborating with Polyrizon to develop an intranasal formulation for enhanced delivery [1] - The company is progressing in its FDA-approved Phase I/IIa trial for alcohol use disorder, with successful cohort completions and upcoming data readouts [1] Future Outlook - Clearmind's leadership emphasizes MEAI's potential as a safer, more effective alternative to current therapies, focusing on behavioral aspects of obesity that hormonal drugs often overlook [1] - The combination of pre-clinical and clinical evidence, intellectual property advancements, and strategic partnerships positions MEAI as a promising solution for sustainable weight management [1]

Approval of FIS Bright Portfolios Focused Equity ETF Reorganization [Accessibility Statement] Skip NavigationSCOTTSDALE, Ariz., Feb. 19, 2026 /PRNewswire/ -- FIS Bright Portfolios Focused Equity ETF (NYSE: BRIF) ("BRIF" or the "Fund") reconvened a special meeting of shareholders earlier today (the "Special Meeting"). At the Special Meeting, the Fund's shareholders were asked to approve an Agreement and Plan of Reorganization pursuant to which BRIF will be reorganized into FIS Trust, as approved by BRIF's Bo ...

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding the efficacy of its drug setrusumab for treating Osteogenesis Imperfecta [1] Summary by Relevant Sections Class Action Lawsuit Details - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, have until April 6, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1] - The lawsuit alleges that Ultragenyx and its executives made false statements and failed to disclose critical information about the Phase III Orbit study, which did not achieve statistically significant results [1] Allegations Against Ultragenyx - The lawsuit claims that Ultragenyx created a false impression of having reliable data on setrusumab's effects while downplaying the risks associated with the Phase III Orbit study [1] - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study failed to achieve statistical significance, leading to a stock price drop of over 25% [1] - Further, on December 29, 2025, the company announced that both the Phase III Orbit and Cosmic studies did not meet primary endpoints, resulting in a stock price decline of more than 42% [1] Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Ultragenyx common stock during the class period to seek lead plaintiff status, representing the interests of all class members [1] - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect an investor's ability to share in any potential recovery [1] About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1]

efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight[Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open- label Phase 3b clinical trial...]### Lilly to participate in TD Cowen's 46th Annual Health Care Conference[Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice...][More Releases From This Source]## Explore[He ...

Kyndryl Holdings, Inc. (KD) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy KD securities between August 7, 2024, and February 9, 2026?Affected Kyndryl Holdings, Inc. Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)] for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the ...

Leidos system installed to help improve efficiency and safety at Reagan National Airport [Accessibility Statement] Skip NavigationRESTON, Va., Feb. 19, 2026 /PRNewswire/ -- Tower controllers and travelers at Washington, D.C.'s Reagan National Airport are expected to experience the benefits of a newly deployed Leidos (NYSE:LDOS) system designed to enhance both the efficiency and safety of flight operations.Developed by Leidos for the Federal Aviation Administration's (FAA) Terminal Flight Data Manager (TFDM) ...

2,800 Teen Deaths. 3x the Risk. Why the First Year Behind the Wheel is the Most Dangerous [Accessibility Statement] Skip NavigationFederal data shows drivers 16-19 are nearly three times more likely to be in a fatal crash – preparation, and protection matter.LOS ANGELES, Feb. 19, 2026 /PRNewswire/ -- The driver's license photo may be slightly awkward, but the milestone is unforgettable. For families, a newly licensed teen means independence, busy schedules — and a new set of responsibilities.Motor vehicle c ...

Shore Bancshares, Inc. Announces Extension of Exchange Offer for its 6.25% Fixed-to-Floating Rate Subordinated Notes Due 2035 [Accessibility Statement] Skip NavigationEASTON, Md., Feb. 19, 2026 /PRNewswire/ -- Shore Bancshares, Inc. (the "Company") (NASDAQ: SHBI), the holding company for Shore United Bank, N.A. (the "Bank"), today announced that it had extended its offer (the "Exchange Offer") to exchange up to $60.0 million aggregate principal amount of its outstanding 6.25% Fixed-to-Floating Rate Subordin ...

Core Viewpoint - Fox Corporation will match the U.S. government's one-time $1,000 contribution to the "Trump Accounts" children's retirement savings program, highlighting its commitment to employee financial well-being [1] Group 1: Company Initiatives - The "Trump Accounts" program is set to launch in July 2026, providing tax-advantaged investment accounts for children born in the U.S. between January 1, 2025, and December 31, 2028 [1] - The contribution match aims to help employees establish a strong financial foundation for their children, promoting savings and investment education [1] Group 2: Company Overview - Fox Corporation produces and distributes news, sports, and entertainment content through brands like FOX News Media, FOX Sports, Tubi Media Group, FOX Entertainment, and FOX Television Stations [1] - The company emphasizes its cultural significance and commercial importance, allowing it to engage audiences and develop consumer relationships effectively [1] - Fox Corporation maintains a strong track record in the news, sports, and entertainment sectors, shaping its strategy for future investments and initiatives [1]